Global Perspectives: Current and Future State of CAR T and Bispecific Antibodies in Hematologic Malignancies 2023
Latest therapeutic developments in CAR T and bispecific agents in hematologic malignancies
Faculty Co-Chair
Elias Jabbour, MD
MD Anderson Cancer Center, Houston, TX, USA
Faculty Co-Chair
Marie José Kersten, MD, PhD
Amsterdam Medical Center, the Netherlands
Faculty Members
Matthew Frigault, MD
Massachusetts General Hospital, Boston, USA
Olivier Tournilhac, MD, PhD
Clermont-Ferrand University Hospital, France
Caron A. Jacobson, MD
Dana-Faber Cancer Institute, Boston, MA, USA
Paolo Corradini, MD
Fondazione IRCCS Istituto Nazionale dei Tumori, Milan, Italy
Georg Hess, MD
Johannes Gutenberg University Mainz, Germany
Daniel DeAngelo, MD, PhD
Dana-Farber Cancer Institute, Boston, MA, USA
Nicola Gökbuget, MD
University Hospital Frankfurt, Germany
Irene Ghobrial, MD
Dana-Farber Cancer Institute, Boston, MA, USA
Keith Stewart, MB, ChB, MBA
University Health Network, Toronto, ON, Canada
REPORT TOPICS INCLUDE
- Update on CAR T in DLBCL
- Update on Bispecific Antibodies in B-NHL
- Update on CAR T in Indolent NHL/MCL and CLL
- Update on CAR T in Leukemias
- Update on Bispecific Antibodies in Leukemias
- Update on CAR T in MM
- Update on Bispecific Antibodies in MM
- Impact of Real-world Data on CAR T-Cell Therapies and Bispecific Antibodies
- Sharing Experiences: Current Barriers for Real-world CAR T Adoption in the US
- Sharing Experiences: Current Barriers for Real-world CAR T Adoption in Europe
